Last winter’s flu epidemic was short and mild. And then COVID-19 arrived. The flu epidemic in the winter of 2019/2020 was mild and lasted only 5 weeks.
Report on the developments of the National Immunisation Programme: national immunisation coverage increased slightly for the first time in five years National immunisation coverage has increased for the first time in five years, for almost all vaccinations. For children born in 2017, vaccination coverage against mumps, measles and rubella (MMR) increased by 0.7% to 93.6%.
More reports of adverse effects of implants in 2019 In 2019, the Dutch reporting centre for adverse effects of medical implants (MEBI) received 397 reports of suspected adverse effects. The reports concerned 462 implants.
Mesh implants intended to treat pelvic organ prolapse Synthetic mesh are used to treat patients with pelvic organ prolapse.
A pregnant woman can protect her baby against whooping cough with 22-week vaccination From 16 December 2019, pregnant women in the Netherlands will be offered the 22-week vaccination. With this vaccination, a pregnant woman protects her child and herself against whooping cough.
Towards a sustainable, healthy future for everyone: EU project INHERIT offers policy solutions Today, on 10 December a policy toolkit will be presented at the final conference of the European four-year research project INHERIT.
Mild 2018-2019 influenza epidemic The annual influenza epidemic in the winter of 2018-2019 was less severe than the year before. Approximately 400,000 people have had the flu.
Summary International Expert Meeting on breast implant-associated lymphoma On November 19th 2018, RIVM organised an international expert meeting on a rare type of lymphoma that is associated with breast implants.
Biosafety and Biosecurity on the Global Health Security Agenda Since 2018, the Netherlands leads the way in the field of "Biosafety and Biosecurity" within the international Global Health Security Agenda (GHSA).
Global Infectious Disease Control hampered by the CBD Nagoya Protocol So far, none of the models used by international networks of biobanks to arrange the legal responsibility under the CBD-Nagoya protocol works efficiently.